HIV/AIDS BRIEF REPORTS
NOTE. Subjects were those for whom follow-up data for defining the incidence of wasting were available. BMI, body mass index.
Weight Loss and Wasting Remain Common Complications in Individuals Infected with Human Immunodeficiency Virus in the Era of Highly Active Antiretroviral Therapy
It has been postulated that the use of highly active antiretroviral therapy (HAART) would reduce the occurrence of human immunodeficiency virus (HIV)-associated weight loss and wasting. To test this assumption, we evaluated, by means of longitudinal analysis, a prospective cohort of 469 HIV-infected individuals enrolled in a study of the impact of HIV on nutrition. Overall, 156 individuals in the cohort (33.5%) met at least 1 of these definitions of wasting. Furthermore, 58% of the cohort (289 patients) lost 11.5 kg of weight in a 6-month period between any 2 study visits. More than 50% of the cohort was receiving HAART at the time that they met 1 of the definitions of wasting; with regard to the occurrence of wasting; no differences were related to therapy.
Weight loss and/or wasting were among the most frequently occurring AIDS-defining conditions in the era before the use of highly active antiretroviral therapy (HAART). The wasting syndrome accounted for ∼18% of the new diagnoses of AIDS in the early 1990s [1] . Since the advent of protease inhibitors in combination with other antiretroviral agents, many of the AIDS-defining, opportunistic illnesses have decreased in frequency [2] . It was assumed that more-effective treatment of HIV infection would also radically reduce the problem of weight loss in this population. However, data from studies that have addressed this issue have not clearly demonstrated that there is an association between suppression of HIV and either maintenance of nutritional status or the return of nutritional status to a normal level [3, 4] . In an attempt to resolve this issue, we have examined baseline and prospective data from a large cohort of HIV-infected individuals for the incidence of weight loss and wasting during a time when the majority of these patients were using HAART.
Subjects are HIV-positive men and women who are enrolled in a longitudinal study (Nutrition for Healthy Living) that began in 1995. The study participants undergo nutritional and Informed consent was obtained from all patients, and US Department of Human Services and New England Medical Center guidelines for human experimentation were followed in this study. health assessments at baseline and at study visits that occur every 6 months. During these assessments, data on weight, height, anthropometry, bioelectrical impedence analysis (BIA), intercurrent medical and medication history, and laboratory parameters of HIV infection, including CD4 cell count and HIV RNA, are collected. In addition, each month, data on current weight, change in medications, and health status were obtained during a telephone interview with each subject. The study was approved by the Human Investigation Review Committee (New England Medical Center, Boston, MA), and patients provided written informed consent.
Any individual who had a loss of 110% of body weight since the baseline visit or who had a body mass index that had fallen to !20 kg/m 2 since the last clinic visit was considered to have wasting. An additional definition of wasting was a loss of 15% of body weight during a 6-month period between clinic visits, with the loss sustained for у1 year. At study visits every 6 months, height and weight were measured on a calibrated scale by trained study personnel.
Height (to the nearest 0.1 cm) was determined by use of a stadiometer, and weight (to the nearest 0.1 kg) was determined by use of a standardized standing beam balance. Body composition was obtained by BIA, which was performed using a Quantum Hand Held Analyzer (RJL Systems, Clinton, MI).
The cohort has enrolled 633 participants; of these, 466 have sufficient follow-up data available for the purpose of defining wasting. Of the group for whom follow-up data were available, 27% were women, 38% were ethnic minorities, 41% had less than a high school education, 48% earned !$10,000 (US) per year, and 56% were living below the federal poverty level. The full spectrum of HIV infection was represented in the cohort: 30% of the participants had CD4 cell counts !200 cells/mm 3 Of the 633 individuals enrolled, 88 (13.9%) reported wasting at the time of their enrollment. These individuals with selfreported wasting at baseline are not included in further analysis. Of the 466 individuals in the cohort, 84 (18%) had lost 110% of body weight since their initial (baseline) study visit (table 1) . Ninety-nine patients (21%) lost 15% of their usual body weight in 6 months, and this weight loss was sustained for у1 year. Thirty-nine patients (8%) were found to have a body mass index In a separate analysis of 497 patients in the cohort, a total of 289 patients (58% of the cohort; 221 males and 68 females) lost 11.5 kg between any 2 study visits made every 6 months (table 2). A cutoff of 1.5 kg was used to ensure that true weight loss, rather than routine scale variation, would be recorded. The mean weight loss in this group of patients was 4.0 kg; of this weight loss, a mean of 1.3 kg was fat-free mass and 2.7 kg was fat mass.
Of the 633 enrollees in the entire cohort, 211 have never used HAART (33%), and 422 have used HAART at some point in time (table 3) . Sixteen of the enrollees who have never used HAART (7.5%) reported wasting at the time of enrollment; an additional 37 (17%) do not have sufficient follow-up data to determine wasting. Of the remaining 158 individuals who have never used HAART, 41 (25.9%) met at least 1 of the definitions of wasting during the course of the study. Of the 422 individuals in the total cohort who have used HAART at some point in time, 72 (17.2%) reported wasting at the time of study entry, and 22 do not have sufficient follow-up data to determine wasting. Of the 328 remaining individuals, 95 (28.9%) met at least 1 of the definitions of wasting during the course of the study. Of the 64 individuals who were not taking HAART when they entered the study and who met at least 1 of the definitions of wasting during the course of the study, 31 (48.4%) met at least 1 of the definitions of wasting after HAART therapy was begun. It appears that the use of HAART has no influence on the development of wasting.
It has been presumed that the problem of weight loss or malnutrition in HIV-infected patients would be eliminated in the era of HAART. Studies that have examined this assumption have found conflicting results.
Studies performed by our group and others have attempted to examine the impact of HAART on the weight loss and body composition of patients who are infected with HIV, and they have found HAART to have varying levels of benefit [3, 4] .
However, these studies have not attempted to address the incidence or prevalence of either weight loss or wasting in the HIV-infected population in the current clinical era.
The definition of wasting, developed by the Centers for Disease Control and Prevention (CDC) in 1987, required an involuntary weight loss of 110% of baseline body weight plus either diarrhea, fever, or weakness for 130 days [5] . Most investigators have dropped the comorbid conditions and have simply used weight loss 110% as the definition of HIV-associated wasting. In this CDC definition, "baseline weight" is not further defined, nor is any time frame for the weight loss specified. Some investigators are using a definition of wasting that requires a weight loss 15% in a 6-month period and that the weight loss be sustained. Wheeler et al. [6] have shown that this level of weight loss can predict mortality and infectious complications in individuals with AIDS. Reduction in a body mass index to !20 kg/m 2 in a 6-month period is also an index of wasting. Because of the current uncertainty as to which of these definitions should be the standard definition of wasting, we have presented data using all 3 criteria.
Nearly 14% of the individuals in our cohort reported wasting, according to the CDC definition (loss of 110% of usual body weight), at the time of enrollment. Although this is self-reported wasting, the prevalence of wasting in this group correlates well with the prevalence of wasting in the population with HIV as a whole [7] . More importantly, a substantial number of participants in the cohort continued to lose weight (58%) or met 1 of the definitions of HIV-associated wasting (33%) during the course of our study, at a time when HAART was in common use.
These data strongly suggest that weight loss and wasting continue to be common problems for individuals infected with HIV. In addition, these complications continue to occur in patients treated with HAART as well as in those for whom HAART has failed or those who cannot tolerate the HAART regimens. 
Dramatic Improvement of Renal Dysfunction in a Human Immunodeficiency Virus-Infected Woman Treated with Highly Active Antiretroviral Therapy
We report a single case documenting substantial improvement in the course of human immunodeficiency virus (HIV)-associated, biopsy-proven nephropathy after introduction of highly active antiretroviral therapy. Our case report joins several others recording improvement or stabilization in the course of nephropathy following better control of HIV replication.
About 5%-10% of HIV-1-infected people will develop nephropathy during the course of HIV disease. HIV-associated nephropathy (HIVAN) is a distinct renal disease in patients infected with HIV. Unfortunately, therapy for this disease has disappointing results, and in many cases, rapid occurrence of end-stage renal disease leads to dialysis and death. Transient improvement of HIVAN has been observed after use of corticosteroids [1] , serum angiotensin-converting enzyme inhibitors [2] , and antiretrovirals (mainly zidovudine) [3] . In the case reported here, we observed a dramatic improvement of renal function in an HIV-infected woman 2 months after initiating highly active antiretroviral therapy (HAART).
A 34-year-old African woman was diagnosed as HIV positive in May 1998 (cervical nodes). Blood creatinine level was normal 18 months before admission (95.5 mmol/L), and no intercurrent medical event occurred. Clinical examination showed no abnormality except for peripheral adenopathies and hypertension (180/100 mm Hg). Laboratory values were as follows: hemoglobin, 8.4 g/dL; reticulocytes, /L; In December 1999, the blood creatinine level was 153 mmol/ L and the viral load was !50 copies/mL. The dosages of epivir and zerit were increased to 150 and 30 mg b.i.d., respectively. Drug levels were not measured, but no side effect or toxicity was reported, and the good virological response indicated efficient serum concentrations.
The pathogenesis of HIVAN is unknown. It is characterized by aggressive glomerulosclerosis, tubulopathy, and interstitial lymphocyte infiltration. Cytokine release and viral proteins may be critical in HIVAN development. Results of experimental studies have shown that viral proteins could enhance apoptosis and may be important determinants of the tubular disease [4, 5] . Until now, no therapy has proved to have long-term efficacy for HIVAN. Recently, however, HAART was successfully used in a patient presenting with acute renal failure due to HIVAN requiring hemodialysis [6] . As reported here, the introduction of antiretroviral therapy at a dosage adjusted to the renal clearance may have made dialysis unnecessary for this patient with stable renal disease, and the therapy was followed by dramatic improvement of renal function. Suppression of retroviral stimulation and subsequent cell damage with HAART could explain its potential benefit in HIVAN. 
The Tolerability of Efavirenz after Nevirapine-Related Adverse Events
Eight patients who were infected with human immunodeficiency virus, and who had each sustained an adverse drug reaction while following a regimen including nevirapine, were switched to a regimen including efavirenz. None of the patients experienced adverse events identical to that which necessitated discontinuation of nevirapine. This study demonstrates that adverse events related to nevirapine are not a class-specific effect.
The standard of care for the treatment of HIV infection involves combination antiretroviral therapy with the use of nucleoside reverse transcriptase inhibitors (NRTIs) with either nonnucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) [1] . NNRTIs are potentially more favorable than PIs, because they are associated with a lower incidence of metabolic abnormalities [2] and because they can be administered in a convenient once-daily dose. Data from clinical trials suggest that the efficacy of NNRTIs is at least equivalent to that of PIs [4, 5] . However, in some patients, poor tolerability may limit use of NNRTIs. The most common adverse event associated with the use of nevirapine (NVP) is a hypersensitivity reaction manifesting as a rash, fever, flulike illness, or hepatitis [2] . Efavirenz (EFV) is associated with a 30% incidence of neurological symptoms, including agitation, insomnia, nightmares, and vivid dreams [3] . A risk of rash and hepatitis is also associated with the use of EFV [3] . Whether a patient can be successfully switched to treatment with EFV after experiencing an adverse event during treatment with NVP has been unclear. We describe a cohort of patients who, after experiencing an NVP-related adverse event, discontinued a regimen including NVP and subsequently switched to a regimen including EFV. We have not studied the role of the other available NNRTI, delaviridine, in such circumstances.
Eight patients (4 homosexual males and 4 females) with a history of injection drug abuse were studied. The mean patient age was 45.7 years (range, 36-75 years). Of the 8 patients, 7 had extensive prior antiretroviral experience, with all 7 having received multiple NRTIs and PIs. None of the patients had previously received an NNRTI. All patients were initially prescribed a regimen of у2 NRTIs with NVP. The reasons for discontinuing NVP treatment in each patient are outlined in table 1. The mean time for onset of NVP-related adverse events was 14.6 days (range, 8 days to 1 month). After a washout period of 7-10 days, treatment was reinstituted with a regimen that included EFV. Five patients have continued following their new regimens for у6 months without having any recurrence of adverse events. Patient 5 was fully compliant with following the regimen for 3 months and experienced no adverse events, but she has since failed to attend for a further medical assessment or a renewal of medication prescriptions. Patient 6 had a facial rash develop 3 months after she initiated her new regimen. This rash was clinically and histologically consistent with eosinophilic folliculitis. Despite receiving therapy for the rash, patient 6 discontinued taking all medications, against medical advice. Patient 7 developed an acute anxiety disorder after 1 month of therapy. This disorder was believed to be secondary to EFV, and the patient's regimen was changed.
Use of NNRTIs has been suggested as part of first-line combination therapy for the treatment of HIV, with potential roles in PI-enhancing, -sparing, or -replacing regimens [1] . The K103N mutation causes broad cross-resistance among members of the NNRTI drug class [6] , and the role of an alternative NNRTI after the failure of an initial member of this class is questionable. However, current guidelines of the International AIDS Society-USA recommend that a single drug in a regimen be changed if it is responsible for an adverse event [1] . With the understanding that the elimination half-life of NVP is 30 h, it can be appreciated that it may take 7 days (i.e., 5 halflives) to ensure that all of the drug is eliminated prior to switching to the use of an alternative drug [2] . This case series shows that adverse events related to NVP are not necessarily a classspecific effect. Our cohort of 8 patients was successfully switched from NVP treatment to EFV treatment without any recurrence of adverse events. 
